Literature DB >> 25037087

Facioscapulohumeral muscular dystrophy.

Jeffrey Statland1, Rabi Tawil2.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is a common type of adult muscular dystrophy and is divided into types 1 and 2 based on genetic mutation. Clinically, both FSHD types often show asymmetric and progressive muscle weakness affecting initially the face, shoulder, and arms followed by the distal then proximal lower extremities. Approximately 95% of patients, termed FSHD1, have a deletion of a key number of repetitive elements on chromosome 4q35. The remaining 5%, termed FSHD2, have no deletion on chromosome 4q35. Nevertheless, both types share a common downstream mechanism, making it possible for future disease-directed therapies to be effective for both FSHD types.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  D4Z4 deletion; DUX4; Facioscapulohumeral muscular dystrophy; Muscular dystrophy; SMCHD1 mutation

Mesh:

Year:  2014        PMID: 25037087      PMCID: PMC4239655          DOI: 10.1016/j.ncl.2014.04.003

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  39 in total

1.  Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy.

Authors:  C Wijmenga; J E Hewitt; L A Sandkuijl; L N Clark; T J Wright; H G Dauwerse; A M Gruter; M H Hofker; P Moerer; R Williamson
Journal:  Nat Genet       Date:  1992-09       Impact factor: 38.330

2.  Strength training and albuterol in facioscapulohumeral muscular dystrophy.

Authors:  E L van der Kooi; O J M Vogels; R J G P van Asseldonk; E Lindeman; J C M Hendriks; M Wohlgemuth; S M van der Maarel; G W Padberg
Journal:  Neurology       Date:  2004-08-24       Impact factor: 9.910

3.  Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study.

Authors:  M C Walter; H Lochmüller; P Reilich; T Klopstock; R Huber; M Hartard; M Hennig; D Pongratz; W Müller-Felber
Journal:  Neurology       Date:  2000-05-09       Impact factor: 9.910

4.  On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy.

Authors:  G W Padberg; O F Brouwer; R J de Keizer; G Dijkman; C Wijmenga; J J Grote; R R Frants
Journal:  Muscle Nerve Suppl       Date:  1995

5.  Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses.

Authors:  K Arahata; T Ishihara; H Fukunaga; S Orimo; J H Lee; K Goto; I Nonaka
Journal:  Muscle Nerve Suppl       Date:  1995

6.  Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. FSH-DY Group.

Authors:  R Tawil; M P McDermott; J R Mendell; J Kissel; R C Griggs
Journal:  Neurology       Date:  1994-03       Impact factor: 9.910

7.  FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit.

Authors:  J C van Deutekom; C Wijmenga; E A van Tienhoven; A M Gruter; J E Hewitt; G W Padberg; G J van Ommen; M H Hofker; R R Frants
Journal:  Hum Mol Genet       Date:  1993-12       Impact factor: 6.150

8.  Camptocormia phenotype of FSHD: a clinical and MRI study on six patients.

Authors:  Berit Jordan; Katharina Eger; Sabrina Koesling; Stephan Zierz
Journal:  J Neurol       Date:  2010-12-17       Impact factor: 4.849

Review 9.  Drug treatment for facioscapulohumeral muscular dystrophy.

Authors:  M R Rose; R Tawil
Journal:  Cochrane Database Syst Rev       Date:  2004

10.  Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. A general association with genetic and therapeutic implications.

Authors:  R B Fitzsimons; E B Gurwin; A C Bird
Journal:  Brain       Date:  1987-06       Impact factor: 13.501

View more
  25 in total

Review 1.  Facioscapulohumeral Muscular Dystrophy.

Authors:  Jeffrey M Statland; Rabi Tawil
Journal:  Continuum (Minneap Minn)       Date:  2016-12

2.  Cis D4Z4 repeat duplications associated with facioscapulohumeral muscular dystrophy type 2.

Authors:  Richard J L F Lemmers; Patrick J van der Vliet; Jeroen P Vreijling; Don Henderson; Nienke van der Stoep; Nicol Voermans; Baziel van Engelen; Frank Baas; Sabrina Sacconi; Rabi Tawil; Silvère M van der Maarel
Journal:  Hum Mol Genet       Date:  2018-10-15       Impact factor: 6.150

3.  Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.

Authors:  Bryan P Fitzgerald; Kelly M Conn; Joanne Smith; Andrew Walker; Amy L Parkhill; James E Hilbert; Elizabeth A Luebbe; Richard T Moxley
Journal:  J Neurol       Date:  2016-10-12       Impact factor: 4.849

4.  AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD.

Authors:  Carlee R Giesige; Lindsay M Wallace; Kristin N Heller; Jocelyn O Eidahl; Nizar Y Saad; Allison M Fowler; Nettie K Pyne; Mustafa Al-Kharsan; Afrooz Rashnonejad; Gholamhossein Amini Chermahini; Jacqueline S Domire; Diana Mukweyi; Sara E Garwick-Coppens; Susan M Guckes; K John McLaughlin; Kathrin Meyer; Louise R Rodino-Klapac; Scott Q Harper
Journal:  JCI Insight       Date:  2018-11-15

5.  Elevated plasma complement components in facioscapulohumeral dystrophy.

Authors:  Chao-Jen Wong; Leo Wang; V Michael Holers; Ashley Frazer-Abel; Silvère M van der Maarel; Rabi Tawil; Jeffrey M Statland; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2022-06-04       Impact factor: 5.121

6.  Electrical impedance myography in facioscapulohumeral muscular dystrophy: A 1-year follow-up study.

Authors:  Karlien Mul; Chad Heatwole; Katy Eichinger; Nuran Dilek; William B Martens; Baziel G M Van Engelen; Rabi Tawil; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2018-04-17       Impact factor: 3.217

7.  Patient-Reported Symptoms in Facioscapulohumeral Muscular Dystrophy (PRISM-FSHD).

Authors:  Johanna Hamel; Nicholas Johnson; Rabi Tawil; William B Martens; Nuran Dilek; Michael P McDermott; Chad Heatwole
Journal:  Neurology       Date:  2019-08-13       Impact factor: 9.910

8.  Sleep-related breathing disorders in facioscapulohumeral dystrophy.

Authors:  Maya Runte; Jens Spiesshoefer; Anna Heidbreder; Michael Dreher; Peter Young; Tobias Brix; Matthias Boentert
Journal:  Sleep Breath       Date:  2019-04-26       Impact factor: 2.655

9.  Design, set-up and utility of the UK facioscapulohumeral muscular dystrophy patient registry.

Authors:  Teresinha Evangelista; Libby Wood; Roberto Fernandez-Torron; Maggie Williams; Debbie Smith; Peter Lunt; Judith Hudson; Fiona Norwood; Richard Orrell; Tracey Willis; David Hilton-Jones; Karen Rafferty; Michela Guglieri; Hanns Lochmüller
Journal:  J Neurol       Date:  2016-05-09       Impact factor: 4.849

10.  Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.

Authors:  Ngoc Lu-Nguyen; Alberto Malerba; Shan Herath; George Dickson; Linda Popplewell
Journal:  Hum Mol Genet       Date:  2021-07-09       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.